These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

443 related items for PubMed ID: 9338484

  • 1. Potentiation of beta-lactams against Pseudomonas aeruginosa strains by Ro 48-1256, a bridged monobactam inhibitor of AmpC beta-lactamases.
    Livermore DM, Chen HY.
    J Antimicrob Chemother; 1997 Sep; 40(3):335-43. PubMed ID: 9338484
    [Abstract] [Full Text] [Related]

  • 2. Effect of conalbumin on the activity of Syn 2190, a 1,5 dihydroxy-4-pyridon monobactam inhibitor of AmpC beta-lactamases.
    Babini GS, Livermore DM.
    J Antimicrob Chemother; 2000 Jan; 45(1):105-9. PubMed ID: 10629020
    [Abstract] [Full Text] [Related]

  • 3. Mutation-driven β-lactam resistance mechanisms among contemporary ceftazidime-nonsusceptible Pseudomonas aeruginosa isolates from U.S. hospitals.
    Castanheira M, Mills JC, Farrell DJ, Jones RN.
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6844-50. PubMed ID: 25182652
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC.
    Cabot G, Bruchmann S, Mulet X, Zamorano L, Moyà B, Juan C, Haussler S, Oliver A.
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3091-9. PubMed ID: 24637685
    [Abstract] [Full Text] [Related]

  • 6. AmpG inactivation restores susceptibility of pan-beta-lactam-resistant Pseudomonas aeruginosa clinical strains.
    Zamorano L, Reeve TM, Juan C, Moyá B, Cabot G, Vocadlo DJ, Mark BL, Oliver A.
    Antimicrob Agents Chemother; 2011 May; 55(5):1990-6. PubMed ID: 21357303
    [Abstract] [Full Text] [Related]

  • 7. Antimicrobial Effects of β-Lactams on Imipenem-Resistant Ceftazidime-Susceptible Pseudomonas aeruginosa.
    Wi YM, Choi JY, Lee JY, Kang CI, Chung DR, Peck KR, Song JH, Ko KS.
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28373200
    [Abstract] [Full Text] [Related]

  • 8. Activity of Ceftolozane-Tazobactam and Ceftazidime-Avibactam against Beta-Lactam-Resistant Pseudomonas aeruginosa Isolates.
    Humphries RM, Hindler JA, Wong-Beringer A, Miller SA.
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28993338
    [Abstract] [Full Text] [Related]

  • 9. WCK 4234, a novel diazabicyclooctane potentiating carbapenems against Enterobacteriaceae, Pseudomonas and Acinetobacter with class A, C and D β-lactamases.
    Mushtaq S, Vickers A, Woodford N, Livermore DM.
    J Antimicrob Chemother; 2017 Jun 01; 72(6):1688-1695. PubMed ID: 28333319
    [Abstract] [Full Text] [Related]

  • 10. In-vitro activity of biapenem, compared with imipenem and meropenem, against Pseudomonas aeruginosa strains and mutants with known resistance mechanisms.
    Chen HY, Livermore DM.
    J Antimicrob Chemother; 1994 May 01; 33(5):949-58. PubMed ID: 8089068
    [Abstract] [Full Text] [Related]

  • 11. Mutations in β-Lactamase AmpC Increase Resistance of Pseudomonas aeruginosa Isolates to Antipseudomonal Cephalosporins.
    Berrazeg M, Jeannot K, Ntsogo Enguéné VY, Broutin I, Loeffert S, Fournier D, Plésiat P.
    Antimicrob Agents Chemother; 2015 Oct 01; 59(10):6248-55. PubMed ID: 26248364
    [Abstract] [Full Text] [Related]

  • 12. Phylogenetic analysis of resistance to ceftazidime/avibactam, ceftolozane/tazobactam and carbapenems in piperacillin/tazobactam-resistant Pseudomonas aeruginosa from cystic fibrosis patients.
    Zamudio R, Hijazi K, Joshi C, Aitken E, Oggioni MR, Gould IM.
    Int J Antimicrob Agents; 2019 Jun 01; 53(6):774-780. PubMed ID: 30831233
    [Abstract] [Full Text] [Related]

  • 13. [Antibiotic susceptibility and occurrence of ESBL in Pseudomonas aeruginosa strains isolated from different clinical specimens].
    Sacha PT, Jakoniuk P, Wieczorek P, Zalewska M, Leszczyńska K.
    Med Dosw Mikrobiol; 2004 Jun 01; 56(3):263-73. PubMed ID: 15773503
    [Abstract] [Full Text] [Related]

  • 14. Evaluation of the In Vitro Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant Pseudomonas aeruginosa Isolates.
    Buehrle DJ, Shields RK, Chen L, Hao B, Press EG, Alkrouk A, Potoski BA, Kreiswirth BN, Clancy CJ, Nguyen MH.
    Antimicrob Agents Chemother; 2016 May 01; 60(5):3227-31. PubMed ID: 26976862
    [Abstract] [Full Text] [Related]

  • 15. Antibiotic resistance and production of extended-spectrum beta-lactamases amongst Klebsiella spp. from intensive care units in Europe.
    Livermore DM, Yuan M.
    J Antimicrob Chemother; 1996 Sep 01; 38(3):409-24. PubMed ID: 8889716
    [Abstract] [Full Text] [Related]

  • 16. Potentiation of ceftazidime by avibactam against β-lactam-resistant Pseudomonas aeruginosa in an in vitro infection model.
    Sy SK, Zhuang L, Beaudoin ME, Kircher P, Tabosa MA, Cavalcanti NC, Grunwitz C, Pieper S, Schuck VJ, Nichols WW, Derendorf H.
    J Antimicrob Chemother; 2017 Apr 01; 72(4):1109-1117. PubMed ID: 28077672
    [Abstract] [Full Text] [Related]

  • 17. Comparative activity of meropenem against Pseudomonas aeruginosa strains with well-characterized resistance mechanisms.
    Livermore DM, Yang YJ.
    J Antimicrob Chemother; 1989 Sep 01; 24 Suppl A():149-59. PubMed ID: 2553657
    [Abstract] [Full Text] [Related]

  • 18. Overexpression of AmpC and efflux pumps in Pseudomonas aeruginosa isolates from bloodstream infections: prevalence and impact on resistance in a Spanish multicenter study.
    Cabot G, Ocampo-Sosa AA, Tubau F, Macia MD, Rodríguez C, Moya B, Zamorano L, Suárez C, Peña C, Martínez-Martínez L, Oliver A, Spanish Network for Research in Infectious Diseases (REIPI).
    Antimicrob Agents Chemother; 2011 May 01; 55(5):1906-11. PubMed ID: 21357294
    [Abstract] [Full Text] [Related]

  • 19. Treatment of experimental pneumonia in rats caused by a PER-1 extended-spectrum beta-lactamase-producing strain of Pseudomonas aeruginosa.
    Mimoz O, Elhelali N, Léotard S, Jacolot A, Laurent F, Samii K, Petitjean O, Nordmann P.
    J Antimicrob Chemother; 1999 Jul 01; 44(1):91-7. PubMed ID: 10459815
    [Abstract] [Full Text] [Related]

  • 20. In Vitro Comparison of Ceftolozane-Tazobactam to Traditional Beta-Lactams and Ceftolozane-Tazobactam as an Alternative to Combination Antimicrobial Therapy for Pseudomonas aeruginosa.
    Goodlet KJ, Nicolau DP, Nailor MD.
    Antimicrob Agents Chemother; 2017 Dec 01; 61(12):. PubMed ID: 28923865
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.